Nontraditional Therapy for Stenotrophomonas maltophilia Infections: Ending the Sulfuring
|
|
- Alannah Cooper
- 6 years ago
- Views:
Transcription
1 Nontraditional Therapy for Stenotrophomonas maltophilia Infections: Ending the Sulfuring Reese Cosimi, Pharm.D., BCPS PGY2 Infectious Diseases Pharmacy Resident South Texas Veterans Health Care System The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center at San Antonio December 9, 2016 Objectives 1. Recognize risk factors and clinical characteristics associated with Stenotrophomonas maltophilia infection 2. Explain mechanisms of Stenotrophomonas maltophilia antimicrobial resistance and its resultant limited susceptibility to traditional agents 3. Recommend optimal antimicrobial therapy for Stenotrophomonas maltophilia in a patient who is not a candidate for trimethoprim-sulfamethoxazole Cosimi 1
2 Background I. History of Stenotrophomonas maltophilia 1 A. Initially isolated from pleural fluid B. Taxonomically reclassified on multiple occasions Figure 1: Nomenclature 1, Bacterium bookeri 1960 Pseudomonas maltophilia 1981 Xanthomonas maltophilia 1993 Stenotrophomonas maltophilia II. Epidemiology A. Incidence 1. Infections due to S. maltophilia occur in 7.4 to 37.7 patients in 10,000 at risk for opportunistic infections 3 2. Isolated in 30% of cystic fibrosis patient sputum cultures 4 B. Mortality 1. Difficult to determine true mortality for several reasons 1 a. Low pathogenicity makes infection versus colonization unclear b. Isolation of S. maltophilia most commonly occurs in critically ill patients c. Poor association with infection and worse clinical outcomes 2. Overall mortality from acute respiratory tract infections was found to be 20.3% though multiple confounders were present 5 a. No evidence of lung consolidation in 70% of patients b. Administration of an antibiotic against S. maltophilia had no effect on outcomes c. Concomitant nosocomial pathogens were present in >30% of patients 3. Attributable mortality with bacteremia is 26.7% and treatment of S. maltophilia improved survival in this population 6 C. Common sources of S. maltophilia 1 1. Soil and plant roots 2. Contaminated fluids a. Dialysate b. Contact solution c. Chlorhexidine d. Sink drains and handwashing soap e. Ice machines Cosimi 2
3 D. Patients at highest risk for isolation of S. maltophilia are those with multiple comorbidities Table 1: Risk Factors 1,6 Malignancy Indwelling devices Chronic respiratory disease Immunocompromised host Prior antibiotic use Prolonged hospitalization ICU admission Chronic conditions E. Typical infectious presentation 1,7 1. Majority of infections are polymicrobial 2. Pneumonia, bacteremia and catheter-related blood stream infections are most common 3. COPD and cystic fibrosis exacerbations, skin and soft tissue infections, osteomyelitis, meningitis, and intraabdominal infections are also seen III. Microbiology 1 A. Yellow colony cultures B. Gram-negative bacilli with polar flagella C. Non-lactose fermenter D. Obligate aerobe E. Oxidase negative F. High affinity to form biofilm on plastic devices Figure 3: Biofilm Formation 9 Cosimi 3
4 G. Clinical and Laboratory Standards Institute (CLSI) breakpoints Table 2: Breakpoints 10 Drug Susceptible Intermediate Resistant TMP-SXT 2/ /76 Minocycline Levofloxacin Ceftazidime TMP-SMX = trimethoprim-sulfamethoxazole IV. Pharmacotherapy A. High rates of intrinsic resistance makes antibiotic selection difficult TMP-SMX is considered treatment of choice Historical data supporting alternative/combination therapy was lacking B. S. maltophilia hospital-acquired pneumonia or ventilator-associated pneumonia 1. Infectious Diseases Society of America (IDSA) makes no recommendations Original in vitro studies demonstrated highest susceptibility with TMP-SMX which supported its utility 11,14,15 C. S. maltophilia catheter-related blood stream infections 1. IDSA guidelines recommend removal of infected device plus TMP-SMX administration Recommendation based on original high susceptibility of TMP-SMX plus evidence that receipt of appropriate therapy decreased mortality by up to 45% 11,17 D. Clinical data using TMP-SMX is lacking ventilator-associated pneumonia patients = 13% mortality bacteremia patients = 0% mortality patients with all infection types = 30.8% mortality 20 V. Pharmacology of agents active against S. maltophilia Table 3: Pharmacology 2 TMP-SMX 16,22 Minocycline 23 Levofloxacin 24 Dose 3-5mg/kg every 8 100mg twice 750mg daily hours daily Route IV or oral IV or oral IV or oral Distribution Vd (L/kg) Cmax (mg/l) Protein Bound (%) TMP: 2; SMX: 0.36 TMP: 3.4; SMX: 46.3 TMP: 44; SMX: Metabolism Hepatic Hepatic None Renal Elimination (%) TMP: Adverse Drug Reactions SMX: Hypersensitivity Nephrotoxicity Hemolytic anemia Thrombocytopenia Hyperkalemia GI upset Hepatotoxicity Photosensitivity Vd = Volume of distribution; CDI = Clostridium difficile infection Tendon rupture CDI Neurotoxicity Prolonged QT Cosimi 4
5 VI. In vitro susceptibility and resistance mechanisms A. Gram-negative pathogens often have multiple intrinsic and acquired mechanisms of resistance 25 Figure 4: Mechanisms of Resistance 26 Figure 4: Mechanisms of Resistance 26 Fluoroquinolones Tetracyclines Beta-lactams Aminoglycoside B. S. maltophilia is resistant to many antimicrobials commonly used for gram-negative infections TMP-SMX 28 a. Mechanism: acquired mobile sul-genes increase bacterial fitness against TMP-SMX b. Increasing prevalence noted worldwide 2. Beta-lactams a. Mechanism: two types of inducible beta-lactamases i. Metallo-beta-lactamase (L1) ii. Clavulanate sensitive cephalosporinase (L2) b. Resistance: All penicillins, cephalosporins and carbapenems c. Ceftazidime and ticarcillin-clavulanate may retain susceptibility though low clinical cure rates have been reported (50 and 60%, respectively) 3. Aminoglycosides a. Mechanism: enzymatic inactivation via acetyltransferase b. Resistance: All aminoglycosides 4. Fluoroquinolones 29 a. Mechanism: efflux pumps and decreased uptake b. Resistance: All fluoroquinolones c. Only levofloxacin has susceptibility breakpoints d. In vitro moxifloxacin is most susceptible but may not equate in vivo 5. Tetracyclines 30 a. Mechanism: efflux pumps and decreased uptake b. Resistance: All tetracyclines Cosimi 5
6 C. Previous antimicrobial exposure significantly increases risk for expression of resistance 11 Table 4: Recent Antibiotic Susceptibility Drug Percent Susceptible (%) Minocycline TMP-SMX 12,31,33-34, Levofloxacin 31-35, Tigecycline Moxifloxacin 12, Ticarcillin-clavulanate 12,34, Piperacillin Ceftazidime 12,31-34, Colistin Ciprofloxacin Gentamicin 32 2 *Antimicrobials without breakpoints required extrapolation from other organisms or drugs in many of these studies VII. Why use alternative agents? A. Hypersensitivity in up to 2% of patients 39 B. Adverse drug reactions in up to 13% of cases 40 C. Thrice daily dosing increases workload and volume burden 21 D. IV formulation drug shortages may take place (most recent: 2014) 41 E. Contraindications to therapy History of sulfonamide- or TMP-induced thrombocytopenia 2. Age <2 months 3. Hepatic damage 4. Megaloblastic anemia due to folate insufficiency 5. Renal insufficiency F. Increasing resistance seen in 30-40% of isolates worldwide 11,28 VIII. Which alternative agent? A. Minocycline and levofloxacin are most attractive alternatives to TMP-SMX 1. High susceptibility rates 2. More favorable adverse drug reaction profiles 3. In vitro analyses demonstrate efficacy IX. Clinical Question A. Do clinical data support non-tmp-smx based therapy as an alternative to TMP-SMX? B. Which situations may it be utilized? Cosimi 6
7 Literature Review Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1): Objective Assess efficacy of fluoroquinolone monotherapy vs. TMP-SMX in S. maltophilia infections Methods Study Design Retrospective review of patients treated with either a fluoroquinolone (ciprofloxacin or levofloxacin) or TMP-SMX for S. maltophilia infections Location: NYU Langone Medical Center, New York, NY Susceptibility breakpoint source: not reported Population Inclusion Criteria Exclusion Criteria 18 years Received combination therapy Positive S. maltophilia culture Clinical signs/symptoms of nosocomial infection Received S. maltophilia treatment for 48 hours Endpoints Microbiological cure and clinical response at end of therapy (EOT), in-hospital mortality, 30-day mortality and nonsusceptible isolates within 30 days of EOT Microbiological cure definition: no growth from same site at or prior to EOT Statistical Categorical data analyzed with chi-squared or Fisher s exact test Analyses Continuous data analyzed with Student s T test or Mann-Whitney U test P-value of <0.05 indicated statistical significance Multivariate logistic regression Results Enrollment 98 patients were included in the review including 35 patients on TMP-SMX and Baseline Characteristics 63 patients on a fluoroquinolone (48 levofloxacin; 15 ciprofloxacin) Characteristic Fluoroquinolone TMP-SMX (n=63) (n=35) Age (mean ± SD) 69±15 73±15 -- Most common underlying conditions, n(%) Major surgery Malignancy (solid organ) Coronary Artery Disease Diabetes mellitus Mechanical ventilation Intra-abdominal drain Most common sites of infection, n(%) Pulmonary Skin/skin structure Urine Intra-abdominal Bacteremia 28 (44) 24 (38) 26 (41) 26 (41) 17 (27) 1 (2) 38 (60) 9 (14) 6 (10) 5 (8) 5 (8) 14 (40) 14 (40) 11 (31) 9 (26) 12 (34) 6 (17) 17 (49) 10 (29) 3 (9) 4 (11) 1 (3) P-value < Prior antibiotic use, n(%) 54 (86) 28 (80) 0.46 ICU Admission, n(%) 17 (27) 6 (17) 0.27 Cosimi 7
8 Length of stay prior to culture, days, median (IQR) Days to treatment, days, median (IQR) Polymicrobial infection, n(%) 53 (84) Pseudmonas spp. 8 (28) Enterococcus spp. 10 (40) Methicillin-resistant 11 (44) Staphylococcus aureus IQR = Interquartile range Results Outcome Fluoroquinolone (n=63) Microbiological cure at 6 (1-19) 4 (0-11) (2-4) 3 (2-5) (63) 2 (22) 5 (38) 3 (31) TMP-SMX P-value (n=35) 23/37 (62%) 13/20 (65%) 0.83 EOT, n(%) In-hospital mortality, (n%) 16/63 (25%) 7/35 (20%) day mortality, n(%) 16/52 (31%) 6/27 (22%) 0.42 Clinical success at EOT, n(%) 27/52 (52%) 17/28 (61%) 0.45 Non-susceptible isolate within 30 11/37 (30%) 4/20 (20%) 0.43 days of EOT, n(%) Duration of therapy, days, median 9 (2-38) 8 (2-28) (IQR) Length of stay, days, median (IQR) 25 (15-37) 16 (8-42) 0.97 Multivariate analysis identified risk factors for increased mortality: o ICU admission (odds ratio, 8.2; 95% confidence interval, ; p = 0.005) o Recent chemotherapy administration (odds ratio, 6.2; 95% confidence interval, ; p = 0.037) High rates of resistance were reported after prior exposure to antibiotics in patients with follow-up cultures o TMP-SMX exposure resulted in 2/7 (24%) resistance to TMP-SMX and 2/5 (40%) resistance to levofloxacin o Fluoroquinolone exposure resulted in 0/11 (0%) resistance to TMP-SMX 10/14 (71%) resistance to levofloxacin and Author s When an alternative to TMP-SMX is required, fluoroquinolones may be used an Conclusions alternative option Discussion Critique Strengths Limitations Take-home Points Combination therapy was an exclusion to the study Follow-up susceptibility testing conducted Adjusted for confounding factors Small retrospective analysis Low proportion of patients could be evaluated for all endpoints Minimal bacteremia patients included in study Resistant isolates excluded No differentiation between colonization and infection Fluoroquinolones may be as efficacious as TMP-SMX in initial treatment of S. maltophilia infections Resistance may develop on therapy but may be more common with fluoroquinolones Cosimi 8
9 Cho SY, Kang C, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1): Objective Compare clinical outcomes of TMP-SMX with levofloxacin against S. maltophilia bacteremia Methods Study Design Retrospective review evaluating outcomes of adult patients receiving either TMP-SMX or levofloxacin for S. maltophilia bacteremia Location: Samsung Medical Center, Seoul, South Korea Susceptibility breakpoint source: CLSI Population Inclusion Criteria Exclusion Criteria 18 years Received either IV TMP-SMX or levofloxacin for S. maltophilia bacteremia for >48 hours Isolate resistant to prescribed therapeutic agent Endpoints Primary objective: Overall 30-day mortality Secondary objectives: Length of stay, adverse events and bacteremia recurrence Statistical Analyses Categorical variables: Fisher s exact test and chi-squared Continuous variables: Student s t test Statistical significance defined as p value <0.05 Multivariate logistic regression utilized to evaluate effects of therapy with levofloxacin Results Enrollment Of 203 patients identified with S. maltophilia 86 were included in the study. TMP-SMX was administered to 51 patients and levofloxacin to 35 patients Rates of susceptibility to initial S. maltophilia isolates were 96.1% for TMP- SMX and 87.1% for levofloxacin Baseline Characteristics Characteristic TMP-SMX Levofloxacin P value (n=51) (n=35) Age, median (IQR) 56 (40-67) 61 (49-68) Gender, male, n(%) 28 (54.9) 28 (80) Source of bacteremia, n(%) Definite catheter-related Possible catheter-related Intrabdominal Pneumonia Underlying disease, n(%) Hematologic malignancy Solid tumor Liver cirrhosis Diabetes mellitus Cardiovascular disease Comorbid conditions, n(%) Central venous catheter Chemotherapy Neutropenia 12 (23.5) 11 (21.6) 14 (27.5) 9 (17.6) 29 (56.9) 16 (31.4) 9 (17.6) 8 (15.7) 8 (15.7) 5 (14.3) 11 (31.4) 11 (31.4) 5 (14.3) 15 (44.1) 16 (45.7) 5 (14.3) 5 (14.3) 8 (22.9) (76.5) 30 (58.8) 25 (49) 22 (62.9) 17 (48.6) 13 (37.1) Catheter removed, n(%) 21 (53.8) 11 (50) Cosimi 9
10 Charlson Comorbidity Index, 2 (2-3) 2 (2-3) median (IQR) Septic shock 13 (25.5) 7 (20) Polymicrobial bacteremia 12 (23.5) 5 (14.3) Combination therapy 9 (17.6) 3 (8.6) Typical daily dose 15-20mg/kg 750mg -- Results Outcome TMP-SMX Levofloxacin P value (n=51) (n=35) 30-day mortality, n(%) 14 (27.5) 7 (20) Length of stay, days, median 23 (12-51) 27 (15-52) (IQR) Adverse events, n(%) 12 (23.5) 0 (0) Recurrent bacteremia, n (%) 6 (11.9) 2 (5.7) Author s Conclusions No difference noted in 30-day mortality with TMP-SMX versus levofloxacin upon exclusion of patients with combination therapy or polymicrobial infections (29% versus 18.5%; p=0.351) Multivariate analysis identified risk factors associated with increased mortality: o Septic shock (odds ratio, 6.19; 95% confidence interval, ; p = 0.004) o Pneumonia (odds ratio, 5.33; 95% confidence interval, ; p = 0.015) Most common adverse events with TMP-SMX reported were rash, cytopenia and hepatotoxicity Half of the recurrent bacteremia isolates were notably resistant to levofloxacin Though clinical trials are needed, levofloxacin may be useful in treating S. maltophilia infections Discussion Critique Strengths Limitations Cohort compared standard of care with levofloxacin Follow-up susceptibility testing conducted Regression analysis conducted to adjust for confounders Only evaluated bacteremia patients Small retrospective analysis Resistant isolates excluded No differentiation between colonization and infection 30-day mortality may not correlate with infection outcomes Take-home Points Levofloxacin may be used for S. maltophilia bacteremia Susceptibility should be determined prior to use as levofloxacin resistance is more common than TMP-SMX Cosimi 10
11 Jacobson S, Noa LJ, Wallace MR, Bowman MC. Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother DOI: /jac/dkw Objective Evaluate efficacy of minocycline for S. maltophilia infections Methods Study Design Retrospective review of patients receiving minocycline for S. maltophilia infections Location: Orlando Regional Medical Center / Orlando Health, Orlando, FL Susceptibility breakpoint source: CLSI Population Inclusion Criteria Exclusion Criteria 18 years Treated with minocycline monoor combination therapy for S. maltophilia Endpoints Clinical failure: Statistical Analyses o o <48 hours of minocycline therapy Pregnant women In-hospital death within 30 days of initial positive culture Clinical deterioration plus one or more of the following: Isolation of S. maltophilia from the same site at follow-up Receipt of an additional antibiotic with in vitro activity against S. maltophilia Partial clinical success: o Lack of clinical deterioration plus one or more of the following: Isolation of S. maltophilia from the same site at follow-up Receipt of additional antibiotics with activity for S. maltophilia Complete clinical success: none of the above Descriptive statistics Results Enrollment 93 of 119 identified patients receiving minocycline for S. maltophilia were included in the review Baseline Characteristics Characteristic Cohort (n=93) ICU, n(%) 49 (53) Mean APACHE II Score, mean (SD) 15 (±6.6) Initial minocycline MIC 4mg/L, n(%) 4mg/L <4mg/L 93 (100) 7 (7.5) 86 (92.5) Infection Type, n(%) Pneumonia Bacteremia 59 (63) 14 (15) Initial Dose 100mg every 12 hours (1 patient received higher dose) Results Outcome Cohort (n=93) Clinical Failure, n(%) 17 (18) Partial Clinical Success, n(%) 22 (24) Complete Clinical Success, n(%) 54 (58) Cosimi 11
12 Patients more likely to fail therapy: o S. maltophilia minocycline MIC 4mg/L (29.4% vs. 2.6%, p=0.004) o Higher mean APACHE II score (18.1 vs. 14.3, p<0.05) Four patients (9%) on minocycline monotherapy reported clinical failure o 3 deaths; 1 had persistently positive cultures with clinical deterioration o All 4 patients had infections with other microorganisms Author s Minocycline may be an appropriate alternative agent for the treatment of S. Conclusions maltophilia but randomized clinical trials are needed Discussion Critique Strengths Limitations Results supported by existing Retrospective analysis literature Included patients on combination Susceptibility testing conducted therapy without specifying agents for correlation with clinical Concomitant infections were outcomes Patients evaluated for partial common in patients with clinical failure clinical success No differentiation between colonization and infection 30-day mortality may not Take-home Points correlate with infection outcomes Minocycline seems to be effective for the treatment of S. maltophilia infections Less clinically ill patients with lower minocycline MICs may benefit most from minocycline therapy Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 2016;71: Objective Evaluate efficacy of minocycline monotherapy vs. TMP-SMX in the treatment of S. maltophilia infections Methods Study Design Retrospective review of patients receiving either minocycline or TMP-SMX for S. maltophilia infections Location: University Hospital, San Antonio, TX Susceptibility breakpoint source: CLSI Population Inclusion Criteria Exclusion Criteria 1 positive culture for S. maltophilia Received 48 hours of minocycline or TMP-SMX as monotherapy Pregnant Incarcerated Received concominant antibiotics with in vitro activity against S. maltophilia during first 48 hours Endpoints Rates of treatment failure in patients with S. maltophilia treated with minocycline vs. TMP-SMX monotherapy Treatment failure definition: Cosimi 12
13 o Isolation of S. maltophilia from same site within 30 days o In-hospital death within 30 days of initial S. maltophilia isolate o Receipt of concomitant antibiotic with in vitro activity against S. maltophilia Statistical Demographics and outcomes: descriptive statistics Analyses Continuous data: Mann-Whitney U-test Nominal data: Chi-squared test Logistic regression analyses conducted to account for confounders P-value of <0.05 indicated statistical significance Results Enrollment 45 patients were included in the review including 23 patients on minocycline and 22 patients on TMP-SMX Baseline Characteristic Minocycline TMP-SMX P-value Characteristics (n=23) (n=22) Age, years, mean (range) 54 (18-81) 49 (8-84) 0.42 Most common comorbid condition, n(%) Mechanical ventilation Chronic lung disease Recent ARI Immunosuppression Malignancy Solid Organ Transplant Most common culture site, n(%) Sputum Broncheoalveolar lavage Blood Leukocytosis upon culture isolation, n(%) 13 (57) 12 (52) 10 (43.5) 8 (35) 8 (35) 6 (26) 9 (39) 7 (30) 1 (5) 10 (45) 2 (9) 2 (9) 3 (14) 3 (14) 2 (9) 8 (36) 5 (23) 1 (5) (52) 12 (55) -- Fever upon culture isolation, n(%) 7 (30) 12 (55) -- ICU Admission, n(%) 17 (74) 14 (64) -- Polymicrobial infections, n(%) P. aeruginosa S. aureus 15 (64) 8 (34) 3 (13) 18 (82) 7 (32) 4 (18) Average daily dose 200mg 8.5mg/kg -- Susceptibility to treatment 23 (100) 22 (100) -- regimen at initiation, n(%) Results Outcome Minocycline TMP-SMX P-value (n=23) (n=22) Treatment failure, n(%) 7 (30) 9 (41) 0.67 S. maltophilia isolated at followup, 5/10 (50) 7/11 (63) 0.75 n(%) Length of stay, days, median 41 (6-136) ) 0.35 (range) 30-day in-hospital mortality, n(%) 2 (8.7) 2 (9) -- Duration of therapy, days, median (range) 13 (4-32) 7 (3-15) Cosimi 13
14 No development of resistance to minocycline was noted upon follow-up cultures and susceptibilities Author s Based on the findings of this study, it is reasonable to use minocycline for S. Conclusions maltophilia infections Discussion Critique Strengths Limitations Evaluated solely monotherapy Small retrospective review with patients inadequate power Cohort compared minocycline to Concomitant infections were standard of care common Adjusted for baseline differences Minimal bacteremia patients Follow-up susceptibility testing conducted Attempted to assess colonization versus infection Take-home Points Minocycline has similar clinical success compared with TMP-SMX for the treatment of S. maltophilia infections and may be used as first-line or alternative therapy for this indication Cosimi 14
15 Conclusions I. Summary A. Evidence continues to grow supporting use of minocycline or fluoroquinolones in the treatment of S. maltophilia B. Levofloxacin is the preferred fluoroquinolone for S. maltophilia based on the presence of CLSI breakpoints and existing clinical data C. Nontraditional therapies may provide equal efficacy as TMP-SMX with more convenient dosing regimens and improved safety profiles II. Recommendations A. TMP-SMX should remain primary therapy for S. maltophilia infections at this time though minocycline susceptibility data supports its use empirically B. When TMP-SMX is not clinically suitable due to contraindications, intolerance, resistant isolates or volume overload, minocycline should be used preferentially to levofloxacin in the treatment of S. maltophilia infections due to the following: 1. Higher rates of susceptibility 2. Better barrier to resistance 3. Superior safety profile 4. Theoretical pharmacokinetic advantages Cosimi 15
16 References 1. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1): Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev. 1998;11(1): Garazi M, Singer C, Tai J, Ginochhio C. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect. 2012;81(2): Davies JC, Rubin BK. Emerging and unusual gram-negative infections in cystic fibrosis. Semin Respir Crit Care Med. 2007;28(3): Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J. 2005;25: Senol E, DesJardin J, Stark P, Barefoot L, Snydman D. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis. 2002;34(12): Al-Anazi KA, Al-Jasser, AM. Infections caused by Stenotrophomonas maltophilia in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4: Stenotrophomonas maltophilia. Microregistrar. Updated: August 19, Accessed: November 11, Center for biofilm engineering: biofilm basics. Montana State University. Accessed: November 11, CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: Clinical Laboratory Standards Institute; Safdar A. (2015). Stenotrophomonas maltophilia and Burkholderia cepacia. In Bennett JE, Dolin R, Blaser MJ, Mandell, Douglas, and Bennette s Principles and Practice of Infectious Diseases, Updated Edition (pp ). Philadelphia: Churchill Livingstone. 12. Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 2016;71: Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5): Fedler KA, Biedenbach DJ, Jones RN Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. 56: Al Johani SM, Akhter J, Balkhy H, et al. Prevalence of antimicrobial resistance among gramnegative isolates in an adult intensive care unit at a tertiary center in Saudi Arabia. Ann Saudi Med. 2010;30(5): Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infections: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49: Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2005;49(9): Czosnowski QA, Wood GC, Magnotti LJ, et al. Clinical and microbiologic outcomes in trauma patients treated for Stenotrophomonas maltophilia ventilator-associated pneumonia. Pharmacotherapy. 2011;31(4): Lakatos B, Jakopp B, Widmer A, et al. Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia. Infection. 2014;42(3): Tekce YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother. 2012;24(3): Cosimi 16
17 21. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: Accessed November 8, Sulfamethoxazole and trimethorpime (sulfamethoxazole/trimethoprim) drug summary. 23. Aqwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2); Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2): Ruppé E, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in gram-negative bacilli. Ann Intensive Care. 2015;5: Resistance mechanisms in bacteria. ReAct. Accessed: November 8, group.org/toolbox/category /understand/the-rise-and-spread-of-antibiotic-resistance/resistancemechanisms-in-bacteria/. 27. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008;62(5): Toleman MA, Bennett PM, Bennett DC, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sulgenes. Emerg Infect Dis. 2007;13(4) Grillon A, Schramm F, Kleinberg M, Jehl F. Comparative activity of ciprofloxacin, levofloxacin and moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia assessed by minimum inhibitory concentrations and time-kill studies. PLoS One. 2016;11(6): Alonso A, Martinez J. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997;41(5): Cikman A, et al. Antibiotics resistance of Stenotrophomonas maltophilia strains isolated from various clinical specimens. Afr Health Sci. 2016;16(1): Sun E, Liang G, Wang L, et al. Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms. Braz J Infect Dis. 2016;20(4): Flamm RK, Castanheira M, Streit JM, Jones RN. Minocycline activity tested against Acinetobacter baumannii, complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis. 2016;85: Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXTsusceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments. PLoS One. 2016;11(3): Wei C, Ni W, Cai X, Cui J. A monte carlo pharmacokinetic/pharmacodynamics simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia. Infect Dis (Lond). 2015;47(12): Jia W, Wang J, Xu H, Li G. Resistance of Stenotrophomonas maltophilia to fluoroquinolones: prevalence in a university hospital and possible mechanisms. Int J Environ Res Public Health. 2015;12(5): Cho SY, Lee DG, Choi SM, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematological malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;15(69): Usta E, Eroglu C, Yanik K, et al. Investigation of the presence of class 1, 2, 3 integrons and their relationships with antibiotic resistance in clinical Stenotrophomonas maltophilia isolates. Mikrobiyol Bul. 2015;49(1): Cosimi 17
18 39. Sanchez-Borges M, Thong B, Blanca M, et al. Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organ J. 2013;6(18): Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. Current Drug Safety. 2013;8: Fox ER, Beckwith MC. Sulfamethoxazole/trimethopriminjection. ASHP. Updated: April 16, Accessed: November 8, Shortages/bulletin.aspx?id= Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 2014;58(1): Cho SY, Kang C, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother. 2014;58(1): Jacobson S, Noa LJ, Wallace MR, Bowman MC. Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother. Doi: /jac/dkw327. Cosimi 18
Tested Against Tigecycline and Agents Commonly Used for S. maltophilia Infections. David J. Farrell 1*, Helio S. Sader 1,2. and. Ronald N.
AAC Accepts, published online ahead of print on 5 April 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.01774-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationTetracycline Rationale for the EUCAST clinical breakpoints, version th November 2009
Tetracycline Rationale for the EUCAST clinical breakpoints, version 1.0 20 th November 2009 Introduction The natural tetracyclines, including tetracycline, chlortetracycline, oxytetracycline and demethylchlortetracycline
More informationMost common dose (mg) 1g x 1 1g x 1 1g x 1 1g x 1 1g x 1 1g x 1. Maximum dose schedule (mg) 1g x 1 1g x 1 1g x 1 1g x 1 1g x 1 1g x 1
Ertapenem Rationale for the EUCAST clinical breakpoints, version 1.3 1 st June 2009 Introduction Ertapenem is a carbapenem, available only for parenteral use. Ertapenem is relevant for therapy of septicaemia,
More informationAntimicrobial Activities of Ceftazidime/Avibactam and Comparator Agents against Clinical. Bacteria Isolated from Patients with Cancer.
AAC Accepted Manuscript Posted Online 23 January 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.02106-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 Antimicrobial Activities
More informationNitroxoline Rationale for the NAK clinical breakpoints, version th October 2013
Nitroxoline Rationale for the NAK clinical breakpoints, version 1.0 4 th October 2013 Foreword NAK The German Antimicrobial Susceptibility Testing Committee (NAK - Nationales Antibiotika-Sensitivitätstest
More informationAntibiotic Resistance in Enterobacteriaceae
Antibiotic Resistance in Enterobacteriaceae Prof. P. Nordmann 16 es JNI, Nancy, du 10 au 12 juin 2015 1 16 es JNI, Nancy, du 10 au 12 juin 2015 16 es JNI, Nancy, du 10 au 12 juin 2015 16 es JNI, Nancy,
More informationEUCAST. Linezolid Rationale for the EUCAST clinical breakpoints, version th November 2005
Linezolid - Rationale document (http://www.eucast.org) 1 (9) Linezolid Rationale for the clinical breakpoints, version 1.0 18 th November 2005 Introduction Linezolid is the only clinically available representative
More informationAntimicrobial Susceptibility of Stenotrophomonas maltophilia Isolates from Korea, and the Activity of Antimicrobial Combinations against the Isolates
ORIGINAL ARTICLE Infectious Diseases, Microbiology & Parasitology http://dx.doi.org/10.3346/jkms.2013.28.1.62 J Korean Med Sci 2013; 28: 62-66 Antimicrobial Susceptibility of Stenotrophomonas maltophilia
More informationGentamicin Rationale for the EUCAST clinical breakpoints, version th February, 2009
Gentamicin Rationale for the EUCAST clinical breakpoints, version 1.2 16 th February, 2009 Introduction The aminoglycosides are a group of naturally occurring or semi-synthetic compounds with bactericidal
More informationA Combination of Trimethoprimsulfamethoxazole. Showed Good In Vitro Activity against. Original Article. Abstract. Introduction
Original Article A Combination of Trimethoprimsulfamethoxazole and Ceftazidime Showed Good In Vitro Activity against Stenotrophomonas maltophilia Nabilah Ismail 1, Zarifah Zam 2, Siti Asma Hassan 1, Zaidah
More informationStenotrophomonas maltophilia bacteremia in pediatric patients a 10-year analysis
Stenotrophomonas J Microbiol Immunol maltophilia Infect bacteremia in children 2006;39:144-149 Original Article Stenotrophomonas maltophilia bacteremia in pediatric patients a 10-year analysis Ping-Sheng
More informationToronto General Hospital ANTIBIOGRAM Emergency Department January 1, December 31, 2016
IV (meningitis) IV (non-meningitis) (meningitis) (non-meningitis) Blood Isolates % Susceptible 644 18 36 70 78 74 59 69 75 262 100 19 64 75 100 92 54 72 78 76 68 89 86 99 Escherichia coli 153 58 30 67
More informationStenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance
Journal of Cystic Fibrosis 10 (2011) 422 427 www.elsevier.com/locate/jcf Original Article Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation
More informationAnalysis of Longitudinal Data. Patrick J. Heagerty PhD Department of Biostatistics University of Washington
Analysis of Longitudinal Data Patrick J Heagerty PhD Department of Biostatistics University of Washington Auckland 8 Session One Outline Examples of longitudinal data Scientific motivation Opportunities
More informationb-lactam resistance and b-lactamase expression in clinical Stenotrophomonas maltophilia isolates having defined phylogenetic relationships
Journal of Antimicrobial Chemotherapy Advance Access published December 13, 2005 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dki453 b-lactam resistance and b-lactamase expression in clinical
More informationA multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan
Journal of Microbiology, Immunology and Infection (2014) 47, 387e393 Available online at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE A multicenter surveillance of antimicrobial
More informationValidation of EUCAST zone diameter breakpoints against reference broth microdilution
ORIGINAL ARTICLE BACTERIOLOGY Validation of EUCAST zone diameter breakpoints against reference broth microdilution S. Bengtsson 1, C. Bjelkenbrant 1 and G. Kahlmeter 1,2 1) Department of Clinical Microbiology,
More informationPseudomonas putida 5
Pseudomonas putida 1 1 2 1 2 1 2 14 1 8 14 12 16 1997 1 21 12 5 Pseudomonas putida 8 27 imipenemipm IPM piperacillinceftazidimeamikacin norfloxacin 27 IPM IMP blaimp P. putida blaimp 27 8 9 4 1 MIC P.
More informationEvaluation of a Stenotrophomonas maltophilia bacteremia cluster in hematopoietic stem cell transplantation recipients using whole genome sequencing
Kampmeier et al. Antimicrobial Resistance and Infection Control (2017) 6:115 DOI 10.1186/s13756-017-0276-y RESEARCH Evaluation of a Stenotrophomonas maltophilia bacteremia cluster in hematopoietic stem
More informationSTUDY ABOUT ANTIBIOTIC RESISTANCE IN SERRATIA SPP. ISOLATED FROM HOSPITALIZED PATIENTS
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 7 (56) No. 1-2014 STUDY ABOUT ANTIBIOTIC RESISTANCE IN SERRATIA SPP. ISOLATED FROM HOSPITALIZED PATIENTS Mihaela Elena
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus
CHAPTER 3 Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus Expert Panel: Mr Mohamed Ezani Md. Taib (Chairperson) Dr Abdul Rais Sanusi Datuk Dr Aizai Azan Abdul Rahim Dr Ashari
More informationCHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus
CHAPTER 3 HEART AND LUNG TRANSPLANTATION Editors: Mr Mohamed Ezani Md. Taib Dato Dr David Chew Soon Ping Dr Ashari Yunus Expert Panel: Mr Mohamed Ezani Md. Taib (Chairperson) Dr Abdul Rais Sanusi Datuk
More informationWhy the CDS? The unique advantages of using an Australian antimicrobial susceptibility testing method
Why the CDS? The unique advantages of using an Australian antimicrobial susceptibility testing method Peter Newton Medical Microbiologist Wollongong Hospital, Wollongong, NSW Where do I come from? SEALS
More informationTHE IDENTIFICATION OF TWO UNKNOWN BACTERIA AFUA WILLIAMS BIO 3302 TEST TUBE 3 PROF. N. HAQUE 5/14/18
THE IDENTIFICATION OF TWO UNKNOWN BACTERIA AFUA WILLIAMS BIO 3302 TEST TUBE 3 PROF. N. HAQUE Introduction: The identification of bacteria is important in order for us to differentiate one microorganism
More informationAntimicrobial therapy for Stenotrophomonas maltophilia infections
Eur J Clin Microbiol Infect Dis (2007) 26:229 237 DOI 10.1007/s10096-007-0279-3 REVIEW Antimicrobial therapy for Stenotrophomonas maltophilia infections A. C. Nicodemo & J. I. Garcia Paez Published online:
More informationRisk Assessment of Staphylococcus aureus and Clostridium perfringens in ready to eat Egg Products
Risk Assessment of Staphylococcus aureus and Clostridium perfringens in ready to eat Egg Products Introduction Egg products refer to products made by adding other types of food or food additives to eggs
More informationEUCAST Expert Rules Version 3.1. Intrinsic Resistance and Exceptional Phenotypes Tables
EUCAST Expert s Version 3.1 Intrinsic Resistance and Exceptional Phenotypes Tables EUCAST Expert s version 2.0 was published on 29 October 2011(http://www.eucast.org/expert_rules). The expert rules have
More informationMost common dose (mg) 1 g x 3 1 g x mg -1.0 g x 3 1 g x mg -1 g x mg -1 g x 3
Meropenem Rationale for the EUCAST clinical breakpoints, version 1.5 1 st June 2009 Introduction Meropenem is a carbapenem, available only for parenteral use. Meropenem is relevant for therapy of septicaemia,
More informationExpression of Sme Efflux Pumps and Multilocus Sequence Typing in Clinical Isolates of Stenotrophomonas maltophilia
Original Article Clinical Microbiology Cho HH, et al. Ann Lab Med 2012;32:38-43 ISSN 2234-3806 eissn 2234-3814 Expression of Sme Efflux Pumps and Multilocus Sequence Typing in Clinical Isolates of Stenotrophomonas
More informationGram negative bacilli
Gram negative bacilli 1-Enterobacteriaceae Gram negative bacilli-rods Enterobacteriaceae Are everywhere Part of normal flora of humans and most animals They are cause of -30-35% septisemia -more than 70%
More informationDepartment of Microbiology and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
ORIGINAL ARTICLE 10.1111/j.1469-0691.2005.01257.x Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital D. Gülmez and G. Hasçelik
More informationAlita Miller, PhD. Head of BioScience. April 24, 2017 ECCMID 2017 Vienna, Austria
ETX5 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo Alita Miller, PhD Head of BioScience April, 07 ECCMID
More informationThe Genetic Epidemiology of Antibiotic Resistance
The Genetic Epidemiology of Antibiotic Resistance Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright The forensics of AMR Resistance
More informationReport: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2014
CODA-CERVA Report: antimicrobial resistance in commensal E. coli from poultry, pigs, cows and veal calves. 2014 Vicky Jasson and Pierre Wattiau Veterinary and Agrochemical Research Centre 1 Introduction
More informationAntimicrobial Resistance in Haemophilus influenzae
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2007, p. 368 389 Vol. 20, No. 2 0893-8512/07/$08.00 0 doi:10.1128/cmr.00040-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Antimicrobial
More informationImplementation of Public Health Surveillance of Carbapenemase- Producing Enterobacteriaceae in Victoria, Australia
Implementation of Public Health Surveillance of Carbapenemase- Producing Enterobacteriaceae in Victoria, Australia C.R. Lane*, J. Brett, M.B. Schultz, K. Stevens, A. van Diemen, S.A. Ballard, N.L. Sherry,
More informationHAEMOPHILUS MODULE 29.1 INTRODUCTION OBJECTIVES 29.2 MORPHOLOGY. Notes
29 HAEMOPHILUS 29.1 INTRODUCTION The genus Haemophilus contains small, nonmotile, nonsporing, oxidase positive, pleomorphic, gram negative bacilli that are parasitic on human beings or animals. Haemophilus
More informationby author ESCMID Online Lecture Library Epidemiological cutoff values (ECOFFs) and Low Level resistance Gunnar Kahlmeter
Epidemiological cutoff values (ECOFFs) and Low Level resistance ECCMID 2010 Gunnar Kahlmeter Sweden Gunnar.Kahlmeter@ltkronoberg.se The epidemiological cutoff value ECOFF When breakpoints fail to detect
More informationExpansion of Salmonella Typhimurium ST34 clone carrying multiple. resistance determinants in China
AAC Accepts, published online ahead of print on 24 June 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01174-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Expansion
More informationAntibiotic resistance by efflux: from molecular aspects to cinical impact
16-09-2013 University of Notre-Dame, Notre Dame, IN 1 Antibiotic resistance by efflux: from molecular aspects to cinical impact Françoise Van Bambeke & Paul M. Tulkens Pharmacologie cellulaire et moléculaire
More informationAntibiotic Resistance in Escherichia coli Iron Transport Mutants
Bowling Green State University ScholarWorks@BGSU Honors Projects Honors College Fall 12-11-2017 Antibiotic Resistance in Escherichia coli Iron Transport Mutants Madeline Brandt mbrandt@bgsu.edu Follow
More informationPHA 4123 First Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.
PHA 4123 First Exam Fall 1998 On my honor, I have neither given nor received unauthorized aid in doing this assignment. TYPED KEY Name Question 1. / pts 2. /2 pts 3. / pts 4. / pts. / pts 6. /10 pts 7.
More informationEfflux Mechanisms of Fluoroquinolones and β-lactams
Efflux Mechanisms of Fluoroquinolones and β-lactams Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels, Belgium
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationWayne State University Doctor of Pharmacy Program. Curriculum and Course Prerequisites Classes of 2017, 2018, and 2019
Wayne State University Doctor of Pharmacy Program Curriculum and Course Prerequisites Classes of 2017, 2018, and 2019 Updated July 10, 2014 P1 Standing = Admission to the Doctor of Pharmacy Program. P2
More informationStudy No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAntibiotic efflux pumps in eucaryotic cells: consequences for activity against intracellular bacteria
Antibiotic efflux pumps in eucaryotic cells: consequences for activity against intracellular bacteria Unité de Pharmacologie cellulaire et moléculaire F. Van Bambeke Magic bullets need to reach their target
More informationIn vitro the effect of intestinal normal flora on some pathogenic bacteria.
In vitro the effect of intestinal normal flora on some pathogenic bacteria. Abstract: Dr.abbass shaker Ali adel Leena abd Al-Redha The effect of two types of intestinal bacterial normal floral ( and klebsiella)
More informationNCCTG Status Report for Study N May 2010
Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI-571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Purpose of - Objectives Study: 1) Study 1: To identify the MTD of imatinib
More informationSample Date: March 30, 2018 Date Received: March 31, 2018 Date of Report: April 9, 2018 (877) Fax: (877)
U.S. Micro-Solutions, Inc. * 075 South Main Street, Suite 04 * Greensburg, PA 560 Phone: (877) 876-4276 Fax: (724) 853-4049 AIHA-LAP, LLC EMLAP #03009 075 South Main Street, Suite 04 Greensburg, PA 560
More informationComparative effectiveness of dynamic treatment regimes
Comparative effectiveness of dynamic treatment regimes An application of the parametric g- formula Miguel Hernán Departments of Epidemiology and Biostatistics Harvard School of Public Health www.hsph.harvard.edu/causal
More informationμ gyra parc Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa E. coli gyra E. coli parc gyra parc gyra Escherichia coli E. coli E.
gyra parc Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa E. coli μ E. coli gyra parc gyra parc gyra parc μ μ gyra parc Key words Escherichia coli gyra parc Escherichia coli E. coli gyra
More informationResearch of New Class C beta-lactamase Inhibitor by Molecular Docking s Method
Journal of Computational Methods in Molecular Design, 2018, 8 (1):26-32 ISSN : 2231-3176 CODEN (USA): JCMMD Research of New Class C beta-lactamase Inhibitor by Molecular Docking s Method Benhamoud Amina,
More informationResearch Article Evaluation of Verigene Blood Culture Test Systems for Rapid Identification of Positive Blood Cultures
BioMed Volume 2016, Article ID 1081536, 6 pages http://dx.doi.org/10.1155/2016/1081536 Research Article Evaluation of Verigene Blood Culture Test Systems for Rapid Identification of Positive Blood Cultures
More informationThe general concept of pharmacokinetics
The general concept of pharmacokinetics Hartmut Derendorf, PhD University of Florida Pharmacokinetics the time course of drug and metabolite concentrations in the body Pharmacokinetics helps to optimize
More informationDepartment of Medical Microbiology, Istanbul University Cerrahpas a Medical Faculty, Istanbul, Turkey; 3 SUMMARY
Le Infezioni in Medicina, n. 1, 27-32, 2017 ORIGINAL ARTICLE 27 Molecular characterization and antibiotic susceptibility of Haemophilus influenzae clinical isolates Hüseyin Kılıç 1, Selcan Akyol 2, Ömür
More informationChronic Granulomatous Disease Medical Management
Chronic Granulomatous Disease Medical Management N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t
More informationAvailable from Deakin Research Online:
This is the published version: Betts, Jonathan, Murphy, Christine, Kelly, Stephen and Haswell, Stephen 2012, Minimum inhibitory and bacterial concentrations of theaflavin and synergistic combinations with
More informationSalmonella enteritidis Identification and Isolation
Department of Microbiology, Qom Branch, Islamic Azad University. Qom, Iran Start Here Advisor Dr.Mohsen Zargar Consulting Advisor Dr.Taghi Salehi Zahraei Presented by Zeinab Yazdanpanah 1 Outcome Enterobacteriaceae
More informationAntibiotic efflux pumps in eucaryotic cells: consequences for activity against intracellular bacteria
Antibiotic efflux pumps in eucaryotic cells: consequences for activity against intracellular bacteria Françoise Van Bambeke on behalf of J.M. Michot, C. Seral, M. Heremans, M.P. Mingeot-Leclercq, P.M.
More informationTyphoid Fever Dr. KHALID ALJARALLAH
Dr. KHALID ALJARALLAH kaljarallah@kfmc.med.sa Main objectives General characteristics (G-, Rod, Facultative anaerobe..etc,) Natural Habitat and transmission root Symptoms Pathogenicity Diagnosis and treatment
More information2 Salmonella Typhimurium
96 2006 Salmonella Typhimurium 2 1) 1) 2) 1) 2) 18 1 10 18 4 27 2 Salmonella Typhimurium 1 7 2 7 (ciprofloxacin (CPFX) MIC 16 mg/ml) S. Typhimurium 2 fosfomycin (FOM) 1 PCR gyra parc RAPD-PCR DNA S. Typhimurium
More informationSerratia marcescens (
103 Serratia marcescens 1 1,2 1,3 1,4 1,5 1 2 3 4 5 Serratia marcescens 2017 5 8.54 4 4.59 ( ) df = 1, 2 = 1.474, P < 0.000 5 S. marcescens 3 2018:28:103-111 Serratia marcescens Serratia marcescens ( )
More informationcefixime CFIX cefteram pivoxil CFTM-PI ceftriaxone CTRX cefodizime CDZM spectinomycin
00 3 STD JR 3 7 7 7 7 0 00 Neisseria gonorrhoeae 77 cefiximecfixcefteram pivoxilcftm-piceftriaxonectrxcefodizimecdzmspectinomycinspcmlevofloxacinlvfx CFIX MIC µ gml 0 pulsed-field gel electrophoresispfge00
More informationBIOL 51A - Biostatistics 1 1. Lecture 1: Intro to Biostatistics. Smoking: hazardous? FEV (l) Smoke
BIOL 51A - Biostatistics 1 1 Lecture 1: Intro to Biostatistics Smoking: hazardous? FEV (l) 1 2 3 4 5 No Yes Smoke BIOL 51A - Biostatistics 1 2 Box Plot a.k.a box-and-whisker diagram or candlestick chart
More informationDistributed analysis in multi-center studies
Distributed analysis in multi-center studies Sharing of individual-level data across health plans or healthcare delivery systems continues to be challenging due to concerns about loss of patient privacy,
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH The First Step: SAMPLE SIZE DETERMINATION THE ULTIMATE GOAL The most important, ultimate step of any of clinical research is to do draw inferences;
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lange P, Celli B, Agustí A, et al. Lung-function trajectories
More informationby author What is new in EUCAST?
What is new in EUCAST? Christian G. Giske, MD/PhD Chair of EUCAST Chief consultant physician/assoc. professor Karolinska Institutet and Karolinska University Hospital ECCMID 2018, Madrid EUCAST SC 2018
More informationMultidrug resistant Stenotrophomonas maltophilia: an emerging cause of hospital acquired infections in Assiut University Hospitals, Egypt
International Journal of Infection Control Multidrug resistant Stenotrophomonas maltophilia www.ijic.info ISSN 19969783 ORIGINAL ARTICLE Multidrug resistant Stenotrophomonas maltophilia: an emerging cause
More informationEffect of iron and sodium chloride on biofilm development of stenotrophomonas maltophilia
Via Sapientiae: The Institutional Repository at DePaul University College of Liberal Arts & Social Sciences Theses and Dissertations College of Liberal Arts and Social Sciences 11-2011 Effect of iron and
More informationPubH 7405: REGRESSION ANALYSIS MLR: BIOMEDICAL APPLICATIONS
PubH 7405: REGRESSION ANALYSIS MLR: BIOMEDICAL APPLICATIONS Multiple Regression allows us to get into two new areas that were not possible with Simple Linear Regression: (i) Interaction or Effect Modification,
More informationThree Steps to Antibiotic Resistance?
Three Steps to Antibiotic Resistance? The Development of Tigecycline Resistance in the Gram-Negative Bacteria Escherichia coli and Salmonella typhimurium Minna-Maria Neuvonen Degree project in biology,
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationEASTERN ARIZONA COLLEGE Microbiology
EASTERN ARIZONA COLLEGE Microbiology Course Design 2015-2016 Course Information Division Science Course Number BIO 205 (SUN# BIO 2205) Title Microbiology Credits 4 Developed by Ed Butler/Revised by Willis
More informationConsiderations with Antibiotic Therapy PART
Considerations with Antibiotic Therapy PART 1 The Wonderful World of Microbiology 1 Despite the promises of the household-products industry, almost every surface is covered in microorganisms almost all
More informationEffluxpumpeninhibitoren alternative Therapiestrategie bei mikrobieller Multiresistenz
Department of Clinical Pharmacology Effluxpumpeninhibitoren alternative Therapiestrategie bei mikrobieller Multiresistenz Markus Zeitlinger Clinical resistancy I MIC time Clinical resistancy II MIC time
More informationCharacterization of Class 1 Integrons and Antimicrobial Resistance in CTX-M-3-Producing Serratia marcescens Isolates from Southern Taiwan
Jpn. J. Infect. Dis., 60, 250-256, 2007 Original Article Characterization of Class 1 Integrons and Antimicrobial Resistance in CTX-M-3-Producing Serratia marcescens Isolates from Southern Taiwan Chien-Fang
More informationIan Morrissey, 1 Samuel K. Bouchillon, 2 Meredith Hackel, 2 Douglas J. Biedenbach, 2 Stephen Hawser, 1 Daryl Hoban 2 and Robert E.
Journal of Medical Microbiology (2014), 63, 556 561 DOI 10.1099/jmm.0.068981-0 Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum
More informationIncreasing Carbapenem-Resistant Gram-Negative Bacilli and Decreasing Metallo-β-Lactamase Producers over Eight Years from Korea
Brief Communication http://dx.doi.org/10.3349/ymj.2015.56.2.572 pissn: 0513-5796, eissn: 1976437 Yonsei Med J 56(2):572-577, 2015 Increasing Carbapenem-Resistant Gram-Negative Bacilli and Decreasing Metallo-β-Lactamase
More informationINTRODUCTION MATERIALS & METHODS
Evaluation of Three Bacterial Transport Systems, The New Copan M40 Transystem, Remel Bactiswab And Medical Wire & Equipment Transwab, for Maintenance of Aerobic Fastidious and Non-Fastidious Organisms
More informationANTIBACTERIAL GRAPHENE OXIDE AND METAL PARTICLES NANOCOMPOSITES FOR INHIBITION OF PATHOGENIC BACTERIA STRAINS
21 st International Conference on Composite Materials Xi an, 20-25 th August 2017 ANTIBACTERIAL GRAPHENE OXIDE AND METAL PARTICLES NANOCOMPOSITES FOR INHIBITION OF PATHOGENIC BACTERIA STRAINS Virginija
More informationAn outbreak of multidrug-resistant Serratia marcescens: The importance of continuous monitoring of nosocomial infections
Clinical science Acta Medica Academica 2013;42(1):25-31 DOI: 10.5644/ama2006-124.67 An outbreak of multidrug-resistant Serratia marcescens: The importance of continuous monitoring of nosocomial infections
More informationBias in Markov Models of Disease
Bias in Markov Models of Disease Daniel M. Faissol, Paul M. Griffin, and Julie L. Swann Stewart School of Industrial and Systems Engineering Georgia Institute of Technology Atlanta, GA 30332-0205 Phone:
More informationDial Complete Foaming Antimicrobial Hand Soap
Dial Complete Foaming Antimicrobial Hand Soap The Dial Corporation Healthcare Division Table of Contents I. Background II. Dial Complete s Key Benefits Superior Germ Kill Superior Mildness Cost Effectiveness
More informationInternational Journal of Pharma and Bio Sciences
Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 CONCORDANCE OF SERUM ELECTROLYTES ON TWO DIFFERENT LAB EQUIPMENTS DRY CHEMISTRY VS. ABG AND ITS IMPORTANCE
More informationCTP-656 Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies
Tablet Confirmed Superiority Of Pharmacokinetic Profile Relative To Kalydeco in Phase I Clinical Studies 39 th European Cystic Fibrosis Conference 8-11 June 2016, Basel, Switzerland 2014 Concert Pharmaceuticals,
More informationCLASSIFICATION OF BACTERIA
CLASSIFICATION OF BACTERIA DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and mitigate potential
More informationThe Clinical Aspects of β-lactam-resistant Stenotrophomonas
Yonago Acta medica 2003;46:91 102 The Clinical Aspects of -Lactam-Resistant Stenotrophomonas maltophilia Daisuke Kataoka and Yoshinori Tanaka Division of Microbiology, Department of Microbiology and Pathology,
More information3 S. Heidelberg ESBL Extended spectrum lactamase
Vol. 25 No. 123 almonella Heidelberg 1 almonella enterica serovar Heidelberg 1 3. Heidelberg EBL Extended spectrum lactamase CTX M 2 EBL. Heidelberg almonella enterica serovar Heidelberg 1 3. Heidelberg
More informationComparison of cefotiam and cefazolin activity against Gram-negative bacilli
Journal of Antimicrobial Chemotherapy (1979) 5, 681-685 Comparison of cefotiam and cefazolin activity against Gram-negative bacilli Michio Ogawa, Masayoshi Hama, Goro Kosaki Second Department of Surgery,
More informationOverview of the major bacterial pathogens The major bacterial pathogens are presented in this table:
Practical Microbiology 30/11/2018 University of Sulaimani college of Pharmacy Year2 Lab. 5: Overview of the major bacterial pathogens The major bacterial pathogens are presented in this table: Major Bacterial
More informationNonlinear pharmacokinetics
5 Nonlinear pharmacokinetics 5 Introduction 33 5 Capacity-limited metabolism 35 53 Estimation of Michaelis Menten parameters(v max andk m ) 37 55 Time to reach a given fraction of steady state 56 Example:
More informationPh.D. course: Regression models. Introduction. 19 April 2012
Ph.D. course: Regression models Introduction PKA & LTS Sect. 1.1, 1.2, 1.4 19 April 2012 www.biostat.ku.dk/~pka/regrmodels12 Per Kragh Andersen 1 Regression models The distribution of one outcome variable
More informationModular Program Report
Modular Program Report Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety
More informationKey words: Staphylococci, Classification, Antibiotic-susceptibility, Opportunistic infection
Key words: Staphylococci, Classification, Antibiotic-susceptibility, Opportunistic infection Table 1. Species classification of staphylococcal isolates from clinical specimens Figures in parentheses indicate
More informationStability. Received for publication 1 August to be fl-lactamase-producing strains.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1978, p. 584-588 0066-4804/78/0013-0584$02.00/0 Copyright X) 1978 American Society for Microbiology Vol. 13, No. 4 Printed in U.S.A. Cefaclor: In Vitro Spectrum
More informationSalmonella empyema: a case report
pneumonia 2015 Nov 17;6:120 124 Case Report Salmonella empyema: a case report Shivanshan Pathmanathan a, Suminda Welagedara a,c, Petra Dorrington b,c, Siddharth Sharma a,c a Department of Medicine, Gold
More informationHypothesis Testing, Power, Sample Size and Confidence Intervals (Part 2)
Hypothesis Testing, Power, Sample Size and Confidence Intervals (Part 2) B.H. Robbins Scholars Series June 23, 2010 1 / 29 Outline Z-test χ 2 -test Confidence Interval Sample size and power Relative effect
More informationObjectives. Epidemiology of AB resistance in S. pneumoniae. Pasteur Institute (R. Vanhoof) AB resistance evaluation (MIC) & mechanisms
Epidemiological survey of susceptibility to β-lactams, macrolides, and fluoroquinolones in a Belgian collection of Streptococcus pneumoniae isolated from patients with CAP A. Lismond, S. Carbonnelle, F.
More information